Secondary sclerosing cholangitis

Summary

Secondary sclerosing cholangitis (MONDO:0018647) is a disease and 4 clinical trials. Top therapeutic interventions include bezafibrate. A subtype of sclerosing cholangitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	secondary sclerosing cholangitis
Mondo ID	MONDO:0018647
Orphanet	447774
SNOMED CT	197442005
UMLS	C0400978
MedGen	586530
GARD	0021869
Is cancer (heuristic)	no

Disease family

This is a subtype of sclerosing cholangitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › non-neoplastic bile duct disorder › cholangitis › sclerosing cholangitis › secondary sclerosing cholangitis

Related subtypes (4): neonatal ichthyosis-sclerosing cholangitis syndrome, primary sclerosing cholangitis, IgG4-related sclerosing cholangitis, isolated neonatal sclerosing cholangitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02701166	PHASE3	UNKNOWN	The Effect of Bezafibrate on Cholestatic Itch
NCT02545309	Not specified	ACTIVE_NOT_RECRUITING	Secondary Sclerosing Cholangitis in Critically Ill Patients
NCT05233553	Not specified	COMPLETED	SSC-COVID in Patients After COVID-19
NCT05396755	Not specified	TERMINATED	Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEZAFIBRATE	3	1
CHEMBL3739769	0	1